Boundless Bio

Update in progress

BOLD (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Boundless Bio, Inc. is a clinical‑stage oncology company developing therapies that target oncogene-amplified cancer using extrachromosomal DNA–directed approaches. Its lead candidate, BBI‑940, is an ecDNA-directed therapeutic in Phase 1/2 for estrogen receptor–positive, HER2‑negative breast cancer and for triple‑negative breast cancer with the luminal AR subtype. Formerly Pretzel Therapeutics, the company changed its name in 2019. Incorporated in 2018 and based in San Diego, California.

Company score

Sentiment: -0.44; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.44; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.29; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive